Almut Scherer

1.8k total citations
53 papers, 1.2k citations indexed

About

Almut Scherer is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Almut Scherer has authored 53 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Rheumatology, 30 papers in Immunology and 11 papers in Hematology. Recurrent topics in Almut Scherer's work include Rheumatoid Arthritis Research and Therapies (40 papers), Spondyloarthritis Studies and Treatments (29 papers) and Psoriasis: Treatment and Pathogenesis (24 papers). Almut Scherer is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (40 papers), Spondyloarthritis Studies and Treatments (29 papers) and Psoriasis: Treatment and Pathogenesis (24 papers). Almut Scherer collaborates with scholars based in Switzerland, United States and Germany. Almut Scherer's co-authors include Axel Finckh, Burkhard Möller, Adrian Ciurea, Michael J. Nissen, Pascale Exer, Giorgio Tamborrini, Cem Gabay, Pascal Zufferey, Raphael Micheroli and Jürg Bernhard and has published in prestigious journals such as PLoS ONE, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Almut Scherer

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Almut Scherer Switzerland	20	1.0k	524	344	122	101	53	1.2k
Gunnstein Bakland Norway	16	909 0.9×	414 0.8×	266 0.8×	60 0.5×	41 0.4×	60	1.1k
Stephan Pflugbeil Austria	7	1.1k 1.0×	205 0.4×	385 1.1×	159 1.3×	30 0.3×	8	1.2k
Kristina Albertsson Sweden	12	756 0.7×	143 0.3×	237 0.7×	114 0.9×	34 0.3×	12	984
Robin Munro United Kingdom	12	551 0.5×	109 0.2×	202 0.6×	110 0.9×	97 1.0×	16	740
Marina Magrey United States	21	910 0.9×	551 1.1×	324 0.9×	34 0.3×	165 1.6×	85	1.3k
Tarnya Marshall United Kingdom	18	519 0.5×	117 0.2×	158 0.5×	90 0.7×	122 1.2×	38	868
Dannette S. Johnson United States	11	529 0.5×	129 0.2×	104 0.3×	85 0.7×	46 0.5×	12	784
I. Speyer Netherlands	15	1.3k 1.3×	171 0.3×	484 1.4×	256 2.1×	28 0.3×	25	1.5k
E. W. Kun China	17	673 0.7×	566 1.1×	181 0.5×	13 0.1×	58 0.6×	31	971
P. M. Houtman Netherlands	16	483 0.5×	225 0.4×	173 0.5×	47 0.4×	33 0.3×	25	768

Countries citing papers authored by Almut Scherer

Since Specialization

Citations

This map shows the geographic impact of Almut Scherer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Almut Scherer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Almut Scherer more than expected).

Fields of papers citing papers by Almut Scherer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Almut Scherer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Almut Scherer. The network helps show where Almut Scherer may publish in the future.

Co-authorship network of co-authors of Almut Scherer

This figure shows the co-authorship network connecting the top 25 collaborators of Almut Scherer. A scholar is included among the top collaborators of Almut Scherer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Almut Scherer. Almut Scherer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riek, Myriam, Almut Scherer, Burkhard Möller, et al.. (2023). Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Scientific Reports. 13(1). 17776–17776. 2 indexed citations

Micheroli, Raphael, Manouk de Hooge, Xenofon Baraliakos, et al.. (2023). Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry. Arthritis Research & Therapy. 25(1). 40–40. 2 indexed citations

Micheroli, Raphael, Kristina Bürki, Burkhard Möller, et al.. (2023). Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. Clinical Rheumatology. 42(9). 2377–2385. 5 indexed citations

Ciurea, Adrian, Kristina Bürki, Pascale Exer, et al.. (2023). Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry. RMD Open. 9(2). e002956–e002956. 8 indexed citations

Micheroli, Raphael, Kristina Bürki, Manouk de Hooge, et al.. (2023). Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years. RMD Open. 9(3). e003340–e003340. 4 indexed citations

Möller, Burkhard, Jennifer Amsler, Adrian Ciurea, et al.. (2023). Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts. Lara D. Veeken. 63(6). 1528–1533.

Scherer, Almut, Andrea Rubbert‐Roth, Axel Finckh, et al.. (2022). Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Lara D. Veeken. 62(1). 89–97. 21 indexed citations

Micheroli, Raphael, Monika Hebeisen, Kristina Bürki, et al.. (2022). HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry. Clinical Rheumatology. 42(5). 1267–1274. 12 indexed citations

Kalweit, Gabriel, Ulrich A. Walker, Axel Finckh, et al.. (2021). Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network. PLoS ONE. 16(6). e0252289–e0252289. 26 indexed citations

10.

Shaw, Yomei, Delphine S. Courvoisier, Almut Scherer, et al.. (2021). Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction. RMD Open. 7(1). e001566–e001566. 16 indexed citations

11.

Neuenschwander, Regula, Monika Hebeisen, Raphael Micheroli, et al.. (2020). Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. Arthritis Research & Therapy. 22(1). 233–233. 31 indexed citations

12.

Ciurea, Adrian, Kristina Bürki, Raphael Micheroli, et al.. (2020). Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases. 80(2). 238–241. 47 indexed citations

13.

Hebeisen, Monika, Regula Neuenschwander, Almut Scherer, et al.. (2018). Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. The Journal of Rheumatology. 45(4). 506–512. 24 indexed citations

14.

Molnar, Christoph, Almut Scherer, Xenofon Baraliakos, et al.. (2017). TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases. 77(1). 63–69. 186 indexed citations

15.

Stekhoven, Daniel J., Almut Scherer, Michael J. Nissen, et al.. (2017). Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clinical Rheumatology. 36(9). 2035–2043. 7 indexed citations

16.

Micheroli, Raphael, Monika Hebeisen, Lukas Wildi, et al.. (2017). Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research & Therapy. 19(1). 164–164. 58 indexed citations

17.

Gabay, Cem, Myriam Riek, Almut Scherer, & Axel Finckh. (2015). Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Lara D. Veeken. 54(9). 1664–1672. 69 indexed citations

18.

Zufferey, Pascal, Burkhard Möller, Laure Brulhart, et al.. (2014). Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study. Joint Bone Spine. 81(5). 426–432. 35 indexed citations

19.

Möller, Burkhard, Menno Pruijm, Sabine Adler, et al.. (2013). Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Annals of the Rheumatic Diseases. 74(4). 718–723. 63 indexed citations

20.

Ciurea, Adrian, Almut Scherer, Pascale Exer, et al.. (2013). Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort. Arthritis & Rheumatism. 65(12). 3096–3106. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact